Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: B

Drug products: Emovat®

ATC code: D07AB01

Substances: clobetasone, clobetasone butyrate


Published controlled studies on differences between men and women regarding efficacy and safety of clobetasone are lacking.

Additional information

Pharmacokinetics and dosing

Topical corticosteroids may be systematically absorbed if used on large areas, on broken skin, or under occlusive dressings [2]. No difference between men and women has been shown for transdermal absorption in general [3].


No studies with a clinically relevant sex-analysis regarding the effects of clobetasone have been found.

Adverse effects

No studies with a clinically relevant sex-analysis regarding adverse effects of clobetasone have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men [1].

Updated: 2020-08-28

Date of litterature search: 2017-02-02


  1. Nyberg F, Osika I, Evengård B. "The Laundry Bag Project"--unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden. Int J Dermatol. 2008;47:144-9. PubMed
  2. Martindale: The Complete Drug Reference. Pharmaceutical Press.
  3. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21. PubMed
  4. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-26.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Linnéa Karlsson Lind